Event
Axxam at BioJapan 2026 | Booth B-07
Ciriaco Maraschiello, CEO
Katie Headland,Vice President Business Development – Europe
6–8 October 2026 | Fiera Milano, Milan, Italy
Axxam will be attending CPHI Milan 2026, bringing together the global pharmaceutical community to connect, exchange ideas and explore new opportunities across the pharma value chain.
From 6 to 8 October, our CEO Ciriaco Maraschiello and Katie Headland, Vice President BD & Sales Europe, will be at Fiera Milano to meet pharmaceutical and biotechnology companies and discuss their drug discovery programs.
If you are attending CPHI Milan, this is an opportunity to connect with our team and explore how Axxam can support your research, from early target biology to screening, hit identification and further characterization.
What does your next discovery challenge look like?
A promising target is only the beginning.
Moving from a biological hypothesis to actionable results can raise very different questions. Is the target sufficiently validated? Which assay best captures its biology? Is the right disease-relevant model available? What screening strategy can identify meaningful starting points for further development?
These decisions can define the direction of an early drug discovery program.
At Axxam, we bring together biology, technology and screening expertise to address these questions with approaches designed around each project.
Our scientists work across diverse target classes and therapeutic areas, developing biochemical, cell-based, functional and phenotypic assays that can be integrated with technologies including High-Content Imaging, electrophysiology and human iPSC-derived models.
From target identification and validation to assay development, high-throughput screening, hit identification and characterization, our capabilities can support individual stages of a project or connect them within a broader discovery workflow.
Different programs. Different starting points.
Some projects arrive with a validated target and need a robust assay for screening. Others require deeper biological characterization before screening can begin. And some start with a phenotype and the need to uncover the biology behind it.
That is why we do not approach every discovery program in the same way.
Axxam combines scientific expertise, technology platforms and extensive compound collections to build discovery strategies around the specific biological question.
Whether you are exploring a challenging target, establishing a new screening cascade or looking for complementary technologies to strengthen an ongoing program, CPHI Milan is a chance to start that conversation in person.
What are you working on next?
Schedule a meeting with our team at CPHI Milan.